IR is an entity where the insulin signaling pathway is altered at several signal transduction points and favors the development of dyslipidemia, obesity, and arterial hypertension (Ruderman et al., 1998; Eckel et al., 2005); then, IR should be considered as part of MetS pathophysiology. The gene discussed is INS; the disease is metabolic syndrome.